[go: up one dir, main page]

MX2019010558A - Peptidos y metodos para el tratamiento de diabetes. - Google Patents

Peptidos y metodos para el tratamiento de diabetes.

Info

Publication number
MX2019010558A
MX2019010558A MX2019010558A MX2019010558A MX2019010558A MX 2019010558 A MX2019010558 A MX 2019010558A MX 2019010558 A MX2019010558 A MX 2019010558A MX 2019010558 A MX2019010558 A MX 2019010558A MX 2019010558 A MX2019010558 A MX 2019010558A
Authority
MX
Mexico
Prior art keywords
diabetes
peptides
treatment
methods
hcpycslqplalegslqkrg
Prior art date
Application number
MX2019010558A
Other languages
English (en)
Inventor
Carlier Vincent
Vander Elst Luc
Saint-Remy Jean-Marie
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of MX2019010558A publication Critical patent/MX2019010558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

La invención se refiere a péptidos tales como HCPYCSLQPLALEGSLQKRG y a su uso en el tratamiento de diabetes tipo 1 y a la generación de célula T CD4+ citolítica.
MX2019010558A 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes. MX2019010558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2019010558A true MX2019010558A (es) 2019-10-21

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010558A MX2019010558A (es) 2017-03-09 2018-03-06 Peptidos y metodos para el tratamiento de diabetes.

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
ES2584430T3 (es) * 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
PE20191529A1 (es) 2017-03-09 2019-10-23 Imcyse Sa Peptidos y metodos para el tratamiento de diabetes
CN114746111A (zh) * 2019-11-27 2022-07-12 易姆赛斯股份公司 用于对糖尿病患者进行分层的方法
JP2023525080A (ja) * 2020-05-06 2023-06-14 アンシス・エスア 新たな酸化還元酵素モチーフを有する免疫原性ペプチド
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
CN115916805A (zh) 2020-05-06 2023-04-04 易姆赛斯股份公司 具有延伸的氧化还原酶基序的免疫原性肽
CA3220752A1 (en) 2021-06-01 2022-12-08 Imcyse Sa Improved methods of treatment using immunogenic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2623391A1 (en) * 2005-09-22 2007-03-29 Yeda Research Development Co. Ltd. Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
PL2059256T3 (pl) 2006-08-11 2017-02-28 Life Sciences Research Partners Vzw Immunogenne peptydy i ich zastosowanie w zaburzeniach immunologicznych
ES2650236T3 (es) * 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
ES2637812T3 (es) 2008-02-14 2017-10-17 Life Sciences Research Partners Vzw Inmunoterapia dirigida a patógenos intracelulares
ES2584430T3 (es) 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
EP2249855B1 (en) 2008-02-14 2017-03-22 Life Sciences Research Partners VZW Immunogenic peptides and their use in transplantation
AR081809A1 (es) 2010-03-29 2012-10-24 Inst Nat Sante Rech Med Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
MX2016005822A (es) 2013-11-04 2016-12-02 Uti Limited Partnership Metodos y composiciones para inmunoterpia sostenida.
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
PE20191529A1 (es) 2017-03-09 2019-10-23 Imcyse Sa Peptidos y metodos para el tratamiento de diabetes
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
KR20190126798A (ko) 2019-11-12
IL268874B1 (en) 2023-05-01
EP3592765A1 (en) 2020-01-15
CN110536898A (zh) 2019-12-03
WO2018162498A1 (en) 2018-09-13
ZA201905851B (en) 2021-04-28
CA3051518A1 (en) 2018-09-13
PH12019502036A1 (en) 2020-06-15
PE20191529A1 (es) 2019-10-23
US20190352348A1 (en) 2019-11-21
CO2019009080A2 (es) 2019-08-30
AU2018229741A1 (en) 2019-08-15
RU2019126232A (ru) 2021-04-10
US20200407406A1 (en) 2020-12-31
CU24596B1 (es) 2022-05-11
IL268874A (en) 2019-10-31
BR112019018616A2 (pt) 2020-04-28
AU2018229741B2 (en) 2021-09-02
JP2020509067A (ja) 2020-03-26
IL268874B2 (en) 2023-09-01
RU2761653C2 (ru) 2021-12-13
JP2022125216A (ja) 2022-08-26
CN110536898B (zh) 2023-09-08
NZ755744A (en) 2023-07-28
US10808016B2 (en) 2020-10-20
US20220411476A1 (en) 2022-12-29
US11760782B2 (en) 2023-09-19
JP7102430B2 (ja) 2022-07-19
CU20190078A7 (es) 2020-04-02
SA519410007B1 (ar) 2023-02-16
MY192295A (en) 2022-08-17
AU2021277735A1 (en) 2021-12-23
SG11201908275XA (en) 2019-10-30
US11407795B2 (en) 2022-08-09
US20240092843A1 (en) 2024-03-21
RU2019126232A3 (es) 2021-06-01

Similar Documents

Publication Publication Date Title
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
MX2019008413A (es) Celulas pluripotentes inmunodiseñadas.
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
AU2017240801A8 (en) Chimeric receptors to FLT3 and methods of use thereof
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
EP4299133A3 (en) Compositions and methods for the delivery of therapeutics
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MA38860B1 (fr) Cellule progénitrice immuno-modulatrice (imp)
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MY193650A (en) Extracellular matrix compositions
MX2018014716A (es) Anticuerpos anti-tnfrsf25.
MX2018011162A (es) Metodos de purificacion de colageno 7.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2019000677A (es) Células miméticas de células b.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
MX2022006022A (es) Peptido derivado de depdc1 y vacuna que lo contiene.
JOP20190101A1 (ar) أنظمة علاج